Dashboard
Manage Tickers

EOLSEvolus, Inc.

Nasdaq evolus.com


$ 11.72 $ 0.28 (2.45 %)    

Monday, 29-Apr-2024 15:59:44 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 433.04 $ 1.75 (0.41 %)
DIA $ 383.81 $ 1.49 (0.39 %)
SPY $ 510.06 $ 1.80 (0.35 %)
TLT $ 88.99 $ 0.74 (0.84 %)
GLD $ 216.18 $ -0.44 (-0.2 %)
$ 11.71
$ 11.61
$ 11.67 x 100
$ 0.00 x 0
$ 11.56 - $ 11.84
$ 7.07 - $ 15.43
612,324
na
666.52M
$ 1.32
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-07-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-02-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-08-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-02-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-03-2022 12-31-2021 10-K
10 11-02-2021 09-30-2021 10-Q
11 08-04-2021 06-30-2021 10-Q
12 05-12-2021 03-31-2021 10-Q
13 03-25-2021 12-31-2020 10-K
14 10-29-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 02-25-2020 12-31-2019 10-K
18 11-04-2019 09-30-2019 10-Q
19 08-12-2019 06-30-2019 10-Q
20 05-01-2019 03-31-2019 10-Q
21 03-20-2019 12-31-2018 10-K
22 11-05-2018 09-30-2018 10-Q
23 08-02-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

evolus-announces-publication-of-safety-and-duration-data-from-phase-2-study-for-extra-strength-40u-formulation-of-jeuveau
Evolus Announces Publication Of Safety and...
04/17/2024 20:13:03

The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appe...

needham-reiterates-buy-on-evolus-maintains-22-price-target
Needham Reiterates Buy on Evolus, Maintain...
04/10/2024 10:47:23

Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
03/21/2024 21:33:35

evolus-reports-pricing-of-50m-offering-of-common-stock
Evolus Reports Pricing Of $50M Offering Of...
03/11/2024 11:03:44

In addition, Evolus has granted the underwriters a 30-day option to purchase up to an additional 533,100 shares of common stock...

stifel-reiterates-buy-on-evolus-raises-price-target-to-25
Stifel Reiterates Buy on Evolus, Raises Pr...
03/08/2024 15:36:41

Stifel analyst Annabel Samimy reiterates Evolus (NASDAQ:EOLS) with a Buy and raises the price target from $23 to $25.

needham-reiterates-buy-on-evolus-maintains-22-price-target
Needham Reiterates Buy on Evolus, Maintain...
03/08/2024 12:08:30

Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.

mizuho-maintains-buy-on-evolus-raises-price-target-to-23
Mizuho Maintains Buy on Evolus, Raises Pri...
03/08/2024 12:07:21

Mizuho analyst Uy Ear maintains Evolus (NASDAQ:EOLS) with a Buy and raises the price target from $20 to $23.

hc-wainwright--co-reiterates-buy-on-evolus-maintains-27-price-target
HC Wainwright & Co. Reiterates Buy on Evol...
03/08/2024 11:56:18

HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $27 price target.

evolus-sees-fy24-total-net-revenues-255m-265m-vs-26117m-est
Evolus Sees FY24 Total Net Revenues $255M-...
03/07/2024 22:08:55

recap-evolus-q4-earnings
Recap: Evolus Q4 Earnings
03/07/2024 21:50:23

evolus-q4-2023-gaap-eps-0210-misses-0200-estimate-sales-60999m-beat-60056m-estimate
Evolus Q4 2023 GAAP EPS $(0.210) Misses $(...
03/07/2024 21:46:28

Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.210) per share which missed the analyst consensus estimate of $(0.200) by...

earnings-scheduled-for-march-7-2024
Earnings Scheduled For March 7, 2024
03/07/2024 09:49:44

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...

earnings-outlook-for-evolus
Earnings Outlook For Evolus
03/06/2024 15:02:19

hc-wainwright--co-reiterates-buy-on-evolus-maintains-27-price-target
HC Wainwright & Co. Reiterates Buy on Evol...
03/01/2024 19:15:39

HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $27 price target.

evolus-announces-results-from-european-head-to-head-filler-trial-european-lift-study-met-the-primary-endpoint-of-non-inferiority
Evolus Announces Results From European Hea...
03/01/2024 13:32:25

  Evolus dermal filler product (Evolysse™/Estyme® Lift) demonstrates statistical superiority at 3 and 6 months compared to Res...

why-panbela-therapeutics-shares-are-trading-lower-by-65-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Panbela Therapeutics Shares Are Tradin...
01/29/2024 19:09:05

Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of...

sofi-technologies-posts-q4-earnings-joins-cardlytics-mcgrath-rentcorp-and-other-big-stocks-moving-higher-on-monday
SoFi Technologies Posts Q4 Earnings, Joins...
01/29/2024 15:31:22

U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOF...

barclays-upgrades-evolus-to-overweight-raises-price-target-to-16
Barclays Upgrades Evolus to Overweight, Ra...
01/29/2024 10:23:35

Barclays analyst Balaji Prasad upgrades Evolus (NASDAQ:EOLS) from Equal-Weight to Overweight and raises the price target fro...

evolus-set-for-promising-2024-analysts-maintain-positive-outlook-on-botox-alternative-maker
Evolus Set For Promising 2024: Analysts Ma...
01/17/2024 20:55:13

Evolus beats Q4 revenue expectations, up 40% YoY at $61M. Full-year 2023 hits $202M, exceeding guidance. Analysts bullish on Ev...

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
01/17/2024 17:31:12

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION